Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

This highly specialised meeting will integrate content from both the former ESMO Sarcoma & GIST Symposium and the ESO-ESMO-RCE Clinical Update on Rare Adult Solid Cancers, bringing  together the most brilliant medical minds working on these tumour types.

ESMO Sarcoma and Rare Cancers 2023

ESMO Sarcoma and Rare Cancers Congress 2023
20–22 March 2023 | Lugano, Switzerland

ESMO Sarcoma and Rare Cancers 2023

ESMO Sarcoma and Rare Cancers Congress 2023
20–22 March 2023 | Lugano, Switzerland
This highly specialised meeting will integrate content from both the former ESMO Sarcoma & GIST Symposium and the ESO-ESMO-RCE Clinical Update on Rare Adult Solid Cancers, bringing  together the most brilliant medical minds working on these tumour types.
Neoadjuvant versus adjuvant treatment chemoradiotherapy in sarcoma 1:24
Neoadjuvant versus adjuvant treatment chemoradiotherapy in sarcoma
Antonia Digklia • 24 Mar 2023
Precision medicine for patients with rare pancreatic malignancies 0:52
Precision medicine for patients with rare pancreatic malignancies
Dirk Arnold • 23 Mar 2023
Unmet needs and future directions in the treating rare pancreatic cancers 1:45
Unmet needs and future directions in the treating rare pancreatic cancers
Dirk Arnold • 23 Mar 2023
Utilizing NGS to identify molecular targets in advanced sarcoma 0:59
Utilizing NGS to identify molecular targets in advanced sarcoma
Antonia Digklia • 24 Mar 2023
Elucidating the first-line therapy approach for the managing ACC 2:43
Elucidating the first-line therapy approach for the managing ACC
Otilia Kimpel • 21 Mar 2023
CCS: present treatment options and current unmet needs 2:04
CCS: present treatment options and current unmet needs
Antonia Digklia • 24 Mar 2023
Identifying alternative molecular targets using NGS in pancreatic cancer 1:43
Identifying alternative molecular targets using NGS in pancreatic cancer
Antonia Digklia • 24 Mar 2023
Repurposing abiraterone for the treatment of AR+ salivary gland carcinomas 1:47
Repurposing abiraterone for the treatment of AR+ salivary gland carcinomas
Alfredo Berruti • 21 Mar 2023
Unmet needs and precision oncology advancements in metastatic GIST 3:19
Unmet needs and precision oncology advancements in metastatic GIST
Robin Jones • 4 Apr 2023
Ripretinib in UK patients with advanced GIST 1:09
Ripretinib in UK patients with advanced GIST
Robin Jones • 4 Apr 2023
Incorporating a tumor agnostic approach in rare cancer clinical trials 2:24
Incorporating a tumor agnostic approach in rare cancer clinical trials
Claudia María Valverde Morales • 30 Mar 2023
What is tumour-agnostic treatment and how is it utilised in rare tumors? 1:16
What is tumour-agnostic treatment and how is it utilised in rare tumors?
Claudia María Valverde Morales • 30 Mar 2023
Unmet needs and the future of tumor agnostic treatment 2:01
Unmet needs and the future of tumor agnostic treatment
Claudia María Valverde Morales • 30 Mar 2023
Employing the use of real-world evidence in the study of ultra-rare cancers 9:01
Employing the use of real-world evidence in the study of ultra-rare cancers
Robin Jones • 4 Apr 2023
Ensuring optimal care in patients with STS following whoops surgery 4:39
Ensuring optimal care in patients with STS following whoops surgery
Piotr Rutkowski • 29 Mar 2023
Vemurafenib and cobimetinib in patients with BRAF-mutated melanoma 4:05
Vemurafenib and cobimetinib in patients with BRAF-mutated melanoma
Piotr Rutkowski • 29 Mar 2023
The content of VJOncology is intended for healthcare professionals